Recent evidence suggests that KRAS mutations are strongly linked to the development of metastasis in specific sites, particularly the lung (62%; 31 out of 50) and brain (56.5%; 26 out of 46), among patients with CRC [66]. The gene discussed is KRAS; the disease is colorectal carcinoma.